Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ultrastructural Analysis of Large Japanese Field Mouse (Apodemus speciosus) Testes Exposed to Low-Dose-Rate (LDR) Radiation after the Fukushima Nuclear Power Plant Accident.
Gatti M, Belli M, De Rubeis M, Tokita S, Ikema H, Yamashiro H, Fujishima Y, Anderson D, Goh VST, Shinoda H, Nakata A, Fukumoto M, Miura T, Nottola SA, Macchiarelli G, Palmerini MG. Gatti M, et al. Among authors: yamashiro h. Biology (Basel). 2024 Apr 4;13(4):239. doi: 10.3390/biology13040239. Biology (Basel). 2024. PMID: 38666851 Free PMC article.
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer.
Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H, Tsuji W, Yamashiro H, Suzuki E, Torii M, Yamada Y, Kataoka T, Ishiguro H, Morita S, Toi M. Takada M, et al. Among authors: yamashiro h. Sci Rep. 2022 Dec 27;12(1):22397. doi: 10.1038/s41598-022-27048-3. Sci Rep. 2022. PMID: 36575361 Free PMC article. Clinical Trial.
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies.
Yamamoto Y, Yamashiro H, Schneeweiss A, Müller V, Gluz O, Klare P, Aktas B, Magdolna D, Büdi L, Pikó B, Mangel L, Toi M, Morita S, Ohno S. Yamamoto Y, et al. Among authors: yamashiro h. Breast Cancer. 2023 Jan;30(1):88-100. doi: 10.1007/s12282-022-01399-1. Epub 2022 Sep 3. Breast Cancer. 2023. PMID: 36057014 Free PMC article.
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Kikawa Y, et al. Among authors: yamashiro h. Breast Cancer. 2022 Sep;29(5):796-807. doi: 10.1007/s12282-022-01357-x. Epub 2022 Apr 23. Breast Cancer. 2022. PMID: 35460066
187 results